MA33740B1 - Traitement à l'aide de cellules adultes matures reprogrammées - Google Patents

Traitement à l'aide de cellules adultes matures reprogrammées

Info

Publication number
MA33740B1
MA33740B1 MA34857A MA34857A MA33740B1 MA 33740 B1 MA33740 B1 MA 33740B1 MA 34857 A MA34857 A MA 34857A MA 34857 A MA34857 A MA 34857A MA 33740 B1 MA33740 B1 MA 33740B1
Authority
MA
Morocco
Prior art keywords
cells
patient
transdifferentiated
treatment
retrodifferentiated
Prior art date
Application number
MA34857A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Ilham Mohamed Saleh Saeed Abuljadayel
Original Assignee
Tristem Trading Cyprus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tristem Trading Cyprus Ltd filed Critical Tristem Trading Cyprus Ltd
Publication of MA33740B1 publication Critical patent/MA33740B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
MA34857A 2009-10-19 2012-05-11 Traitement à l'aide de cellules adultes matures reprogrammées MA33740B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2009/051396 WO2011048350A1 (en) 2009-10-19 2009-10-19 Treatment using reprogrammed mature adult cells

Publications (1)

Publication Number Publication Date
MA33740B1 true MA33740B1 (fr) 2012-11-01

Family

ID=42199514

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34857A MA33740B1 (fr) 2009-10-19 2012-05-11 Traitement à l'aide de cellules adultes matures reprogrammées

Country Status (16)

Country Link
EP (1) EP2490702A1 (ja)
JP (1) JP6073135B2 (ja)
KR (1) KR101766203B1 (ja)
CN (1) CN102647989A (ja)
AU (1) AU2009354350B2 (ja)
CA (1) CA2781522A1 (ja)
CH (1) CH704227B1 (ja)
CU (1) CU24006B1 (ja)
IL (1) IL218902A (ja)
MA (1) MA33740B1 (ja)
MX (1) MX2012004522A (ja)
RU (1) RU2635317C2 (ja)
TN (1) TN2012000157A1 (ja)
UA (1) UA109265C2 (ja)
WO (1) WO2011048350A1 (ja)
ZA (1) ZA201202664B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107075470A (zh) 2014-09-18 2017-08-18 北卡罗来纳大学 哺乳动物肺球体和肺球体细胞及其应用
JP6113133B2 (ja) 2014-11-06 2017-04-12 日本メナード化粧品株式会社 幹細胞の未分化状態維持剤及び増殖促進剤
CA3001859A1 (en) 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
CN107114355A (zh) * 2016-08-01 2017-09-01 北京世纪劲得生物技术有限公司 一种脂肪细胞保护液及其制备方法
MX2019010196A (es) * 2017-02-28 2019-12-19 Vor Biopharma Inc Composiciones y métodos para la inhibición de proteínas específicas del linaje.
CN109731012A (zh) * 2017-10-30 2019-05-10 邹兆中 提高生物免疫治疗有效物质活性的方法
CN109706119B (zh) * 2018-04-13 2020-11-27 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN113423725A (zh) 2018-08-28 2021-09-21 Vor生物制药股份有限公司 遗传工程化造血干细胞及其用途
KR20200025210A (ko) * 2018-08-29 2020-03-10 주식회사 스템모어 모유두 세포의 배양용 조성물 및 이를 이용한 모유두 세포의 배양 방법
WO2021240204A1 (en) * 2020-05-23 2021-12-02 Pakravan Nafiseh Sperm head for resolution of inflammation, tissue repair & regeneration, and restoration of tissue function: new approach of cell therapy
CN114231481B (zh) * 2021-12-21 2023-07-18 中国人民解放军总医院 一种重编程真皮成纤维细胞为内皮祖细胞的化学诱导方法
CN117025504A (zh) * 2022-05-10 2023-11-10 上海赛立维生物科技有限公司 胆囊前体样细胞的制备方法和应用
WO2024050517A1 (en) * 2022-09-02 2024-03-07 The University Of North Carolina At Chapel Hill Methods of making and using anticancer reprogrammed b cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US9068164B1 (en) * 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
US7112440B2 (en) * 1995-02-02 2006-09-26 Ghazi Jaswinder Dhoot Method of increasing the relative number of CD45 low cells in a cell population
WO1996035224A1 (en) * 1995-05-02 1996-11-07 Philips Electronics N.V. Colour cathode ray tube
US20050037490A1 (en) * 1999-10-29 2005-02-17 Lawrence Rosenberg Medium for preparing dedifferentiated cells
TWI288779B (en) * 2002-03-28 2007-10-21 Blasticon Biotech Forschung Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
WO2006014642A1 (en) * 2004-07-22 2006-02-09 Five Prime Therapeutics, Inc. Method of producing autologous embryonic stem cells
WO2010115052A2 (en) * 2009-04-03 2010-10-07 The Mclean Hospital Corporation Induced pluripotent stem cells

Also Published As

Publication number Publication date
CU24006B1 (es) 2014-06-27
RU2012120713A (ru) 2013-11-27
RU2635317C2 (ru) 2017-11-10
AU2009354350B2 (en) 2015-09-03
JP2013508343A (ja) 2013-03-07
WO2011048350A1 (en) 2011-04-28
MX2012004522A (es) 2012-05-08
AU2009354350A1 (en) 2012-04-19
EP2490702A1 (en) 2012-08-29
ZA201202664B (en) 2013-02-27
IL218902A0 (en) 2012-06-28
UA109265C2 (uk) 2015-08-10
CU20120063A7 (es) 2012-10-15
KR20120099686A (ko) 2012-09-11
CH704227B1 (fr) 2015-05-15
JP6073135B2 (ja) 2017-02-01
KR101766203B1 (ko) 2017-08-08
IL218902A (en) 2017-06-29
CA2781522A1 (en) 2011-04-28
CN102647989A (zh) 2012-08-22
TN2012000157A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
MA33740B1 (fr) Traitement à l'aide de cellules adultes matures reprogrammées
Dawidson et al. Sensory stimulation (acupuncture) increases the release of calcitonin gene-related peptide in the saliva of xerostomia sufferers
WO2006015214A3 (en) Umbilical cord stem cell composition & method of treating neurological diseases
WO2012071526A3 (en) Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
EP1671627B8 (en) Improvement of cell therapy and tissue regeneration in patients with cardiovascular and neurological diseases by means of shockwaves
CL2007001165A1 (es) 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares.
EP2465923A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
Alcocer-Gómez et al. Effect of coenzyme Q10 on psychopathological symptoms in fibromyalgia patients
EA201891507A1 (ru) Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе
NO20076382L (no) Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer
JP5030553B2 (ja) ドライマウスおよび／または唾液分泌障害を処置するための医薬
JP2015199733A (ja) 眼圧降下剤
IL172499A0 (en) Method for producing retinal nerve cells from stem/progenitor cells derived from iris tissue and retinal nerve cells obtained by same method
RU2012136724A (ru) Лечение или профилактика инфекции
Wang et al. Low-intensity pulsed ultrasound prompts both functional and histologic improvements while upregulating the brain-derived neurotrophic factor expression after sciatic crush injury in rats
ATE466574T1 (de) Verfahren und zusammensetzungen zur oralen fts- abgabe
CN204890221U (zh) 一种牙种植体个性化基台
Liu et al. The roles, mechanism, and mobilization strategy of endogenous neural stem cells in brain injury
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
Abdanipour et al. Effect of hydro-ethanolic extract of Chamaemelum nobile on cell prolifration and apoptosis of rat hipocample neural stem cells in the oxitative stress condition
DE602006019759D1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
AR058796A1 (es) Oligonucleotidos estimulantes de l a proliferacion de celulas madre mesenquimatosas y sus usos
Jie-wen et al. p75 neurotrophin receptor positive dental pulp stem cells: new hope for patients with neurodegenerative disease and neural injury
MX2022001287A (es) Composiciones y metodos de uso de celulas madre multipotentes para reducir la enfermedad y mejorar el bienestar.
Zhao et al. Potassium titanate assembled titanium dioxide nanotube arrays endow titanium implants excellent osseointegration performance and nerve formation potential